Details for New Drug Application (NDA): 215110
✉ Email this page to a colleague
NDA 215110 describes MAVYRET, which is a drug marketed by Abbvie and is included in two NDAs. It is available from one supplier. There are ten patents protecting this drug. Additional details are available on the MAVYRET profile page.
The generic ingredient in MAVYRET is glecaprevir; pibrentasvir. One supplier is listed for this compound. Additional details are available on the glecaprevir; pibrentasvir profile page.
The generic ingredient in MAVYRET is glecaprevir; pibrentasvir. One supplier is listed for this compound. Additional details are available on the glecaprevir; pibrentasvir profile page.
Summary for 215110
| Tradename: | MAVYRET |
| Applicant: | Abbvie |
| Ingredient: | glecaprevir; pibrentasvir |
| Patents: | 8 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 215110
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 215110
Suppliers and Packaging for NDA: 215110
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| MAVYRET | glecaprevir; pibrentasvir | PELLETS;ORAL | 215110 | NDA | AbbVie Inc. | 0074-2600 | 0074-2600-28 | 1 PACKET in 1 CARTON (0074-2600-28) / 28 PELLET in 1 PACKET |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | PELLETS;ORAL | Strength | 50MG;20MG/PACKET | ||||
| Approval Date: | Jun 10, 2021 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jun 10, 2028 | ||||||||
| Regulatory Exclusivity Use: | FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A); AND TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH | ||||||||
| Regulatory Exclusivity Expiration: | Dec 10, 2028 | ||||||||
| Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Dec 10, 2030 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Complete Access Available with Subscription
